NgoSepthemba 27, iwebhusayithi esemthethweni ye-CDE yabonisa ukuthi isicelo senkomba entsha ye-Pfize Crisaborole cream (igama lokuhweba laseShayina: Sultanming, igama lokuhweba lesiNgisi: Eucris a, Staquis) samukelwe, okungenzeka ukuthi senzelwe izingane kanye nabantu abadala abaneminyaka eyizinyanga ezi-3 futhi abantu abadala abane-atopic dermatitis.

I-Crisaborole iyi-molecule encane, engeyona i-hormonal, i-nonsteroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor eyakhiwe yi-Anacor.NgoMeyi 2016, uPfizer wathola inkampani ngo-$5.2 billion futhi wathola umuthi.NgoZibandlela wonyaka ofanayo, i-Crisaborole yagunyazwa yi-FDA ukuze imakethwe, yaba umuthi wokuqala kadokotela we-atopic dermatitis owavunywa eminyakeni eyi-10, kanye nomuthi wokuqala wangaphandle ongeyona i-steroidal ukuvimbela i-PDE4 yesikhumba.

I-Crisaborole Inhibitors njengesidakamizwa esisha, empeleni, amafomu omthamo womlomo asetshenziselwe i-plaque psoriasis ephakathi futhi eqinile kanye ne-psoriatic arthritis, umphumela oyinhloko wokungakhululeki emathunjini, ayikho enye ibala elikhethekile.

I-Crisaborole njengezidakamizwa ze-Topical, ingena kancane esikhumbeni, amathuba alo mphumela ohlangothini wokungakhululeki kwamathumbu nawo ancishiswa abe aphansi kakhulu.

Ngenxa yalokho, i-Crisaborole ngokuzumayo yaba "ithemba ledolobhana lonke" kusukela eminyakeni engu-15, odokotela nabazali bebemagange ukuba nokusetshenziswa okuphephile, okuphumelelayo kanye nesikhathi eside kwezidakamizwa ze-topical kude kakhulu.

Usebenza kangakanani umuthi nge-Crisaborole?

Ngo-2016, izifundo ezimbili zesilingo somtholampilo zeSigaba III zaletha izindaba ezijabulisa kakhulu, i-Crisaborole, amafutha okugcoba ama-phosphodiesterase-4 (PDE4) inhibitors, ezigulini ezine-atopic dermatitis engaphezu kweminyaka engu-2 ubudala (izingane kanye nabantu abadala), bathole imiphumela emihle yomtholampilo.